Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanostart-holding MagForce Receives Further Patent Related to NanoTherm Therapy

Abstract:
- European patent granted for nanoparticle-drug conjugates
- MagForce expands patent portfolio

Nanostart-holding MagForce Receives Further Patent Related to NanoTherm Therapy

Berlin / Frankfurt Germany | Posted on May 7th, 2013

Nanostart-holding MagForce, a leading medical technology company in the field of nanomedicine in oncology, announced today that the Company has been granted a further European patent for its NanoTherm therapy, for which the opposition period has now expired. Patent EP 1871423 B1 relates to a new generation of NanoTherm particles in the form of nanoparticle-drug conjugates, which are suitable for drug delivery systems.

Nanoparticle-drug conjugates inside a tumor can be heated selectively by an alternating magnetic field leading to a temperature-dependent release of the drug inside the tumor tissue producing a high local drug concentration. Additionally the known synergistic effects of chemotherapy in combination with hyperthermia can be utilized.

"The locally limited and externally controllable drug release by means of the now patent-protected conjugates is expected to clearly reduce the mostly considerable side-effects of conventional chemotherapeutic agents. Combining thermotherapy with nanoparticle-bound chemotherapy could also substantially increase the effectiveness of the chemotherapeutic agent in tumor treatment and reduce the number of nanoparticles required to destroy the cancer cells," commented Prof. Dr. Hoda Tawfik, COO and co-CEO of MagForce. "We are very pleased to have been granted a further patent for our NanoTherm therapy. By expanding our patent portfolio we will improve protection of our intellectual property and strengthen our competitive position."

####

About Nanostart AG
Nanostart AG is a leading nanotechnology venture capital company. The company invests venture capital (VC) in promising young nanotechnology companies. Nanostart invests globally and at different phases of development. Emphasis of investments is on especially innovative industries such as cleantech, life sciences, and IT/electronics. Nanostart invests either directly in nanotechnology companies or through a regional nanotechnology fund. The headquarters of Nanostart AG is in Frankfurt, Germany.

About MagForce AG

MagForce AG is a leading medical technology company in the field of nanomedicine in oncology. The Company's proprietary, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm®, NanoPlan®, and NanoActivator™ are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com


About NanoTherm Therapy

The NanoTherm Therapy is a new approach for the local treatment of solid tumors. The principle of the method is the direct introduction of superparamagnetic nanoparticles into a tumor and their subsequent heating in an alternating magnetic field. The nanoparticles are extremely small (approximately 15 nanometers in diameter) and contain an iron oxide core with an aminosilane coating. The particles are activated by a magnetic field that changes its polarity 100,000 times per second, and heat is produced. Depending on the duration of treatment and the achieved intratumoral temperatures, the tumor cells are either directly destroyed (thermal ablation) or sensitized for concomitant chemotherapy or radiotherapy (hyperthermia). With this new therapeutic approach, it is possible to combat the tumor from the inside out, thereby sparing surrounding healthy tissue. The nanoparticles remain in place at the treatment area, allowing for repeat treatments and the integration of multimodal therapy concepts. NanoTherm® Therapy has regulatory approval in 27 European countries.

Disclaimer

This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia, or Japan.

For more information, please click here

Contacts:
Nanostart AG
Dr. Hans Joachim Dürr
Head of Corporate Communications
Goethestrasse 26-28
60313 Frankfurt/Main
P: +49 69-21 93 96 111
F: +49 69-21 93 96 150

Copyright © Nanostart AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Gold standards for nanoparticles: Understanding how small organic ions stabilize gold nanoparticles may allow for better control March 29th, 2017

Tiny sensor lays groundwork for precision X-rays detection via endoscopy:Nanoscale fiber-integrated X-ray sensor opens new doors for medical imaging and radiotherapy March 29th, 2017

Researchers uncover secret of nanomaterial that makes harvesting sunlight easier March 29th, 2017

Information storage with a nanoscale twist: Discovery of a novel rotational force inside magnetic vortices makes it easier to design ultrahigh capacity disk drives March 28th, 2017

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Caught on camera -- chemical reactions 'filmed' at the single-molecule level March 22nd, 2017

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

TriboTEX Uses Nanotechnology to Improve the Efficiency of Old Vehicles March 13th, 2017

Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017

Nanomedicine

Gold standards for nanoparticles: Understanding how small organic ions stabilize gold nanoparticles may allow for better control March 29th, 2017

Tiny sensor lays groundwork for precision X-rays detection via endoscopy:Nanoscale fiber-integrated X-ray sensor opens new doors for medical imaging and radiotherapy March 29th, 2017

Laser activated gold pyramids could deliver drugs, DNA into cells without harm: Microstructures create temporary pores in cells March 27th, 2017

Researchers make flexible glass for tiny medical devices: Glass can bend over and over again on a nanoscale March 27th, 2017

Announcements

Gold standards for nanoparticles: Understanding how small organic ions stabilize gold nanoparticles may allow for better control March 29th, 2017

Tiny sensor lays groundwork for precision X-rays detection via endoscopy:Nanoscale fiber-integrated X-ray sensor opens new doors for medical imaging and radiotherapy March 29th, 2017

Researchers uncover secret of nanomaterial that makes harvesting sunlight easier March 29th, 2017

Information storage with a nanoscale twist: Discovery of a novel rotational force inside magnetic vortices makes it easier to design ultrahigh capacity disk drives March 28th, 2017

Patents/IP/Tech Transfer/Licensing

Laser activated gold pyramids could deliver drugs, DNA into cells without harm: Microstructures create temporary pores in cells March 27th, 2017

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

Intertronics introduce new nanoparticle deagglomeration technology March 15th, 2017

Keystone Nano Announces The US FDA Has Awarded Orphan Drug Designation For Ceramides For The Treatment Of Liver Cancer November 8th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project